Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

Slides:

Advertisements

Similar presentations

Natural History of Prostate Cancer Local therapy Androgen deprivation therapy (ADT) Therapies after ADT Death ADT mCRPC post- docetaxel mCRPC symptomatic.

Advertisements

Intermediate Atypical Carcinoma: Novel Histologic Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists CCO Independent Conference Highlights.

CCO Independent Conference Coverage

Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.

The Role of Statistics in Clinical Trials

New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.

Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

Updates and Insights on the Medical Science of Prostate Cancer

NOACs for Cancer-Associated Thrombosis:

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Optimizing Therapy for Osteoarthritis

The Challenge of Bone-Metastatic PC

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

When Is Adding Aspirin to NOACs Worth the Risk?

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

Glaucoma Progression.

The Nurse View.

At The Cutting Edge of Developments in the Management of Hyperkalemia

PAD Patients vs Post-ACS Patients:

Unmet Needs in the Secondary Prevention in ACS

Epidemiology Venous Pathophysiology Etiology.

Metastatic Renal Cell Carcinoma

PCP Perspectives Clinical Considerations in Hyperkalemia

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

New Treatments for CTEPH

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Activity Goals. Activity Goals Case Presentation.

Best Practices in Metastatic Colorectal Cancer

VTE Treatment Conventional Approach

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.

Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.

Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Hyperkalemia in the Hospital

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Better Diabetes Control With Novel Basal Insulins

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

The Road to Quality Improvement in HER2-Positive Breast Cancer

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

Cancer-Associated Thrombosis

CAD and HF Often Coexist

Implications of Emerging Treatments for Beta-Thalassemia

Treatment of Locally Advanced Pancreatic Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Proteasome Inhibitors and Patients

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Preparing for Checkpoint Inhibitors in Breast Cancer

Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.

A Multidisciplinary Perspective on the Management of Hypoparathyroidism.

Assessing the Burden of Hyperkalemia

Program Goal. Program Goal Disclaimer Overview.

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES

New Paradigms in M0 CRPC.

Getting PPG Under Control

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

AMD Therapy: Where Are We Now and Where Are We Going?

Assessing the Burden of Hyperkalemia

Third-Generation EGFR TKIs

Real-World Evidence.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Evaluating the Totality of Evidence

What's New in Oral Combination Therapy for Type 2 Diabetes?

Uncovering the Right Sequence

Presentation transcript:

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice

Program Goals

Prostate Cancer Overview

mCRPC Current Treatment Options

ALSYMPCA Trial Design

ALSYMPCA Efficacy and Safety Data

ALSYMPCA 3-Year Follow-up Safety Data

International EAP Safety Data

International EAP OS by Patient Baseline Characteristics

Ra-223 Completion of Therapy Variables

International EAP OS by Concomitant Medications

mCRPC Bone Markers and OS

mCRPC Ra-223 + Docetaxel

Novel AR Antagonist ARN-509

Novel AR Antagonist ODM-201

Moving CRPC Care Forward Take Home Points

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)